Attorney Docket No.: NOVV-003/00US





IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

in re Application of: Robin ROBINSON et al.

Confirmation No.: 5752

Application No.: 10/617,569

Group Art Unit: 1648

Filed: July 11, 2003

Examiner: Myron G. Hill

For: FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPs)

U.S. Patent and Trademark Office Customer Service Window Randolph Building 401 Dulany Street Alexandria, VA 22314

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

[X]	Pursuant to 37 C.F.R. §1.98, a copy of each non-US patent document cited in the attached Form PTO/SB/08 is enclosed.
0	No copies of the publications, with the exception of the publication listed as cite no, a copy of which is attached, listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No to which the above-identified application claims priority under 35 U.S.C. §120.
[]	No copies of any U.S. patents or U.S. patent application publications listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98.
0	Publication(s) listed on the attached Form PTO/SB/08 were cited in a foreign search or examination report corresponding to application serial no and mailed on
	Enclosed is a copy of a non-English publication(s) Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).

Attorney Docket No.: NOVV-003/00US Application No.: 11/617,569 Page 2

		ed is a copy of a non-English publication(s) English language ation (copy enclosed) claims priority from this non-English ation.					
		Enclosed is an explanation of non-English publication(s) for which an English translation is not available.					
	Enclosed is an English translation of non-English publication(s)cited in the attached Form PTO/SB/08.						
[]	Enclos	ed is a copy of pending patent Application Serial No					
This Ir		on Disclosure Statement is filed after the period specified in 37 § 1.97(b), but before the mailing of:					
[x]	a final action under 37 C.F.R. §1.113;						
[]	a notice of allowance under 37 C.F.R. §1.311; or						
[]	an action that otherwise closes prosecution in this application.						
	In accordance with 37 C.F.R. §1.97(c) also enclosed is:						
	[x]	Fee under 37 C.F.R. §1.17(p) in the amount of \$180.00; or					
	[]	Statement as specified in 37 C.F.R. §1.97(e):					
		[] Each item of information contained in the Information Disclosure Statement cited herein was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing date of the Information Disclosure Statement; or					
		No item of information contained in the Information Disclosure Statement submitted herewith was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, having made a reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three months prior to the filing date of the Information Disclosure Statement.					

Attorney Docket No.: NOVV-003/00US

Application No.: 11/617,569

Page 3

It is respectfully requested that the Examiner consider the above-noted information and return an initialed copy of the attached Form PTO/SB/08 to the undersigned.

By:

Respectfully submitted,

COOLEY GODWARD KRONISH-LLP

Edward I. Amaya Reg. No. 54,960

Dated: 10/18/00

CUSTOMER NO. 58249

COOLEY GODWARD KRONISH LLP

ATTN: Patent Group The Bowen Building 875 15th Street NW, Suite 800

875 15th Street NW, Suite 800 Washington, DC 20005-2221

Tel: (202) 842-7800 Fax: (202) 842-7899

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

W TRADE	Complete if Known	
Application Number	10/617,569	\neg
Filing Date	July 11, 2003	
First Named Inventor	Robin ROBINSON et al.	
Group Art Unit	1648	
Examiner Name	Myron G. Hill	
Attorney Docket Number	NOVV-003/00US	

			U.S. PATE	NT DOCUMENTS		
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant Cited Document	Pages, Columns, Lines, Where R Passages or Relevant Figures A	
	<u> </u>					
	!	<u> </u>	, FOREIGN PA	TENT DOCUMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
						<u> </u>
				LITERATURE DOCUMENT		
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				
	1.	Avalos, Roy, et al., "Association of Influenza Virus NP and M1 Proteins with Cellular Cytoskeletal Elements in Influenza Virus-Infected Cells," Journal of Virology, Apr. 1997, Vol. 71, pp. 2947-2958				
_	2.	Bucher, D., et al., "M Protein (M1) of Influenza Virus: Antigenic Analysis and Intracellular Localization with Monoclonal Antibodies," <i>Journal of Virology</i> , Sept. 1989, Vol. 63, pp. 3622-3633				
	3.	Chen, Ze, et al., "Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza," Vaccine, 1998, Vol. 16, 1544-1549.				
	4.	Chen, Ze, et al., "Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase- expressing DNAs," Vaccine, 1999, Vol. 17, 653-659.				
	5.	Enami, Masayoshi and Enami, Kazue, "Influenza Virus Hemagglutinin and Neuraminidase Glycoproteins Stimulate the Membrane Association of the Matrix Protein," <i>Journal of Virology</i> , Oct. 1996, Vol. 70, pp. 6653-6657				
	6.	Huylebroeck, Danny, et al., "High-level transient expression of influenza virus proteins from a series of SV40 late and early replacement vectors," Gene, 1988, Vol. 66, pp. 163-181				
	7.	Kretzschmar, Evelyne, et al., "Membrane Association of Influenza Virus Matrix Protein Does Not Require Specific Hydrophobic Domains or the Viral Glycoproteins," Virology, 1996, Vol. 220, pp. 37-45				
	8.	Zhang, Jie and Lamb, Robert, "Characterization of the Membrane Association of the Influenza Virus Matrix Protein in Living Cells," <i>Virology</i> , Vol. 225, pp. 225-266				
Examiner Signature				Date Considered	rough citation if not in conformance and not c	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, Include copy of this form with next communication to applicant. ¹Unique citation designation number (optional). ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BEST AVAILABLE COPY